Favipiravir CAS 259793-96-9

Description:

Recommendation time: novel coronavirus, chloroquine, and Chinese patent medicine have been found

to have a number of marketed drugs that are resistant to new coronavirus in February 4th, Sun Yanrong,

deputy director of the Biotechnology Center of the Ministry of science and technology, told the news

conference of the national health and Health Committee.

Expert evaluation: on February 15, at the press conference of the joint prevention and control mechanism

of the State Council, Zhang Xinmin, director of the biological center of the Ministry of science and technology,

said that fabiravir is an overseas listed drug for the treatment of influenza. At present, clinical trials have been

carried out in Shenzhen, with more than 70 patients in the group, including the control group, initially showing

a more obvious effect and a lower adverse reaction. On the 3rd to 4th day after treatment, the negative rate of

viral nucleic acid in the treatment group was significantly higher than that in the control group.

Specifications:

Application:

Our strengths:

We can customize according to customer’s requirement.

If you have any question pls mail us or call us.